Skip to main content
Back
HOCPF logo

HOYA Corporation

Data quality: 100%
HOCPF
OTC Healthcare Medical - Instruments & Supplies
$175.79
$0.00 (0.00%)
Mkt Cap: 59.43B
Also listed as HOCPY OTC
Day Range
$175.79 $187.00
52-Week Range
$96.42 $191.23
Volume
155
50D / 200D Avg
$172.84 / $147.75
Prev Close
$175.79

Price History

Financial Trends

Peer Comparison

vs Healthcare sector median (627 peers)

Metric Stock Sector Median
P/E 0.3 0.3
P/B 0.1 2.9
ROE % 20.8 3.7
Net Margin % 22.8 3.8
Rev Growth 5Y % 12.8 10.0
D/E 0.0 0.2

Analyst Price Target

No analyst coverage available

Earnings Estimates

Period EPS Est. Revenue Est. Analysts
FY2030 $1,235.33
$1,194.14 – $1,265.27
 1300 B 1
FY2029 $1,063.64
$1,028.17 – $1,089.41
 1200 B 1
FY2028 $885.88
$856.34 – $907.35
 1100 B 1

Key Takeaways

Revenue grew 12.76% annually over 5 years — strong growth
ROE of 20.82% indicates high profitability
Net margin of 22.82% shows strong profitability
Debt/Equity of 0.04 — conservative balance sheet
Generating 187.19B in free cash flow
P/E of 0.29 — trading at a low valuation

Growth

Revenue Growth (5Y)
12.76%
Revenue (1Y)11.76%
Earnings (1Y)11.43%
FCF Growth (3Y)5.45%

Quality

Return on Equity
20.82%
ROIC35.66%
Net Margin22.82%
Op. Margin54.28%

Safety

Debt / Equity
0.04
Current Ratio4.90
Interest Coverage329.54

Valuation

P/E Ratio
0.29
P/B Ratio0.06
EV/EBITDA-0.91
Dividend Yield0.01%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 11.76% Revenue Growth (3Y) 10.64%
Earnings Growth (1Y) 11.43% Earnings Growth (3Y) 9.47%
Revenue Growth (5Y) 12.76% Earnings Growth (5Y) 12.66%
Profitability
Revenue (TTM) 885.82B Net Income (TTM) 202.10B
ROE 20.82% ROA 16.37%
Gross Margin 86.50% Operating Margin 54.28%
Net Margin 22.82% Free Cash Flow (TTM) 187.19B
ROIC 35.66% FCF Growth (3Y) 5.45%
Safety
Debt / Equity 0.04 Current Ratio 4.90
Interest Coverage 329.54 Dividend Yield 0.01%
Valuation
P/E Ratio 0.29 P/B Ratio 0.06
P/S Ratio 0.07 PEG Ratio 2.33
EV/EBITDA -0.91 Dividend Yield 0.01%
Market Cap 59.43B Enterprise Value -437.25B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 885.82B 792.63B 723.58B 661.47B 547.92B
Net Income 202.10B 181.38B 168.64B 164.51B 125.45B
EPS (Diluted) 581.26 515.27 469.47 445.93 335.25
Gross Profit 766.25B 687.99B 631.86B 567.28B 474.98B
Operating Income 480.79B 433.45B 346.38B 317.02B 263.74B

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 1.23T 1.20T 1.03T 992.84B 853.29B
Total Liabilities 262.65B 241.36B 213.72B 203.78B 180.88B
Shareholders' Equity 974.02B 967.76B 818.32B 803.85B 688.00B
Total Debt 37.28B 29.24B 24.58B 21.60B 20.75B
Cash & Equivalents 533.97B 525.16B 405.89B 419.40B 334.90B
Current Assets 879.73B 856.64B 710.16B 682.97B 554.58B
Current Liabilities 179.51B 168.91B 156.10B 147.38B 131.61B

Strategy Scores

This stock passed the criteria for 7 strategies

Score = fit strength (0–100)
Rank = position among all matches
Custom Cash Flow Compounder
#486 of 1052
46
Custom Capital Light Compounder
#70 of 218
49
Custom Deep Value Investing (Seth Klarman)
#400 of 827
43
Growth Price/Sales Ratio Focus (Ken Fisher)
#516 of 618
14
Custom Contrarian Investing (David Dreman)
#549 of 670
10
Value Defensive Investing (Benjamin Graham)
#563 of 709
11
Value Value Investing (Warren Buffett)
#169 of 203
30

Recent Activity

Entered Cash Flow Compounder
Mar 24, 2026
Entered Deep Value Investing (Seth Klarman)
Mar 24, 2026
Entered Capital Light Compounder
Mar 24, 2026
Entered Price/Sales Ratio Focus (Ken Fisher)
Mar 24, 2026
Entered Contrarian Investing (David Dreman)
Mar 24, 2026
Entered Defensive Investing (Benjamin Graham)
Mar 24, 2026
Entered Value Investing (Warren Buffett)
Mar 24, 2026